Sagimet Biosciences (SGMT) Cash from Financing Activities (2022 - 2025)

Sagimet Biosciences' Cash from Financing Activities history runs 4 years deep, the most recent figure standing at $274000.0 for Q3 2025.

• In Q3 2025, Cash from Financing Activities changed N/A year-over-year to $274000.0; the TTM figure through Dec 2025 stood at $274000.0 (down 99.74% YoY), while the FY2025 annual figure was $275000.0, down 99.74% from the prior year.
• Cash from Financing Activities for Q3 2025 stood at $274000.0, up from -$27000.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $104.8 million in Q1 2024, with the low at -$910000.0 in Q2 2023.
• The 4-year median for Cash from Financing Activities is -$27000.0 (2024), against an average of $27.3 million.
• Peak annual rise in Cash from Financing Activities reached 77192.65% in 2024, while the deepest fall reached 97.03% in 2024.
• Sagimet Biosciences' Cash from Financing Activities stood at -$55000.0 in 2022, then soared by 158669.09% to $87.2 million in 2023, then plunged by 100.03% to -$27000.0 in 2024, then surged by 1114.81% to $274000.0 in 2025.
• Business Quant data shows SGMT's Cash from Financing Activities at $274000.0 in Q3 2025, -$27000.0 in Q2 2024, and $104.8 million in Q1 2024.